



# Meta Analyses: Benefits & Pitfalls

C.J. Sniffen  
Fencrest, LLC  
Holderness, NH

I.J. Lean  
SBScibus  
Australia



# Meta Analyses: Benefits and Pitfalls

## Introduction

- In the last 10 years we have seen many papers using meta analysis in the dairy area
- Looking at various nutritional subjects
- Determining the value of different products
- This is a tool that has been used in the human medical & social sciences for many years
- Many recommendations have been made in human health based on these analyses  
(see Cochrane Collaboration @ [cochrane.org](https://www.cochrane.org))



# Meta Analyses: Benefits and Pitfalls

## Introduction

- We often have conflicting and confusing nutritional results when looking at several individual papers
- Meta analysis is a statistical tool that allows us to achieve an empirical and maybe more mechanistic understanding of the effects of a practice or product
- In an unbiased manner using a scientifically valid approach
- Our focus today is to show some positive results and outline some of the principles of valid meta analyses



# Meta Analyses: Benefits and Pitfalls

## Why Do a Meta-Analysis?

- We often have a substantial body of literature using a particular intervention
  - Changing a nutritional parameter
  - Inclusion of a feed component
- Doing a quantitative analysis we can obtain an estimate of
  - The average effect
  - The distribution around the effect
- Evaluate the variability or consistency in responses to the intervention
- Identify if evidence is probably missing



# Meta Analyses: Benefits and Pitfalls

## Why Do a Meta-Analysis?

- In practical terms
- We can provide a much better estimate of the likely overall effect of the intervention
  - With a confidence interval around the intervention
  - Also an assessment can be provided on the likelihood of seeing a response
  - This can also allow us to estimate the return on the investment



# Meta Analyses: Benefits and Pitfalls

## Why Do a Meta-Analysis?

- We will be able to better identify the factors affecting the response
- We can provide better guidelines as to which groups the intervention will provide an economic response
  - For example, close-up, fresh, high, late lactation
- We can provide the producer a better estimate of the effect of the intervention
- Give them confidence around the estimate
  - Where or when to apply the intervention for best effects



# Meta Analyses: Benefits and Pitfalls


## Why Do a Meta-Analysis?

- The analyses will also provide the basis to design experiments to answer new questions that were uncovered from the analyses – it is a research project in it's own right



# Meta Analyses: Benefits and Pitfalls

## Schematic Representation of the Meta-Analytic Process







# Meta Analyses: Benefits and Pitfalls


## Selection of Studies to Use in Meta-Analyses

- If we are trying to understand the long term effects of an intervention on
  - Full Lactation, Early lactation, Transition
- Including studies with designs such as Latin squares is not suggested
  - Reduced variance will over-weight the studies
  - Unfortunately we are many times forced into the use of these studies due to a limited database for the intervention
- Randomized controlled studies preferred



# Meta Analyses: Benefits and Pitfalls

## Differences in Weights from Randomized Controlled Studies<sup>0</sup> and Latin Squares<sup>1</sup>





# Meta Analyses: Benefits and Pitfalls

## Positive and Negative Attributes of Classical and Other Meta-Analyses

Positive Attributes	Classical	Other
A clear hypothesis	✓	✓
Comprehensive literature search at least three databases	✓	✓
Clearly defined criteria for inclusion or exclusion	✓	✓
Tables detailing studies extracted and data obtained	✓	✓
Measures of outcome analyzed	Odds ratios (OR), relative risk (RR), continuous variables, hazard ratios (from survival analysis), incidence rates	Continuous variables can be extended to logistic regression methods



# Meta Analyses: Benefits and Pitfalls


## Positive and Negative Attributes of Classical and Other Meta-Analyses

Positive Attributes	Classical	Other
Outcomes	Pooled OR, RR, standard mean difference, meta regression, confidence intervals	Weighted, regression means, confidence intervals
Estimates of Heterogeneity (sources of variation)	✓	✓
Examination of Heterogeneity	✓	✓
Sensitivity analysis of powerful studies	✓	✓
Publication bias	Funnel plots	



# Meta Analyses: Benefits and Pitfalls

## Forest Plot – Effect of GnRH on the RR for Pregnancy in Repeat Breeder Cows





# Meta Analyses: Benefits and Pitfalls

## Summary - GnRH

- A producer can use GnRH as an intervention that will provide a 24% increased chance of repeat breeder cows becoming pregnant
- Looking at the variance there were 4 studies that there was not a significant difference
- What other information can be obtained from these studies that would help the producer make a more informed decision for the use of GnRH?
- Would there be an opportunity get a better understanding of the biology to design new studies?



## Meta Analyses: Benefits and Pitfalls


### Use of the Standardized Mean Difference (SMD)

- Useful in continuous trials such a milk production.
- $SMD = (\text{Exp. group mean} - \text{control group mean}) / \text{pooled SD of the groups}$ 
  - Accounts for study size and variance
- Can pool different measurement scales for the same measure



# Meta Analyses: Benefits and Pitfalls

## Forest Plot – SMD – Milk Production of Cows Supplemented with Biotin with Other Cows









# Meta Analyses: Benefits and Pitfalls

## Forest and Funnel Plots: Milk yield response to fats (Rabiee et al 2012)





# Meta Analyses: Benefits and Pitfalls


## The Funnel Plot Use

- Used to examine publication bias
- The assumption is that the largest studies will be near the average effect
- The small studies will be spread on both sides of the average effect
  - Even distribution demonstrates no bias
  - An asymmetric distribution suggests bias
    - A relationship to study size and treatment effect



# Meta Analyses: Benefits and Pitfalls


## Begg's Funnel Plot – Effect of Monensin on Milk Yield





# Meta Analyses: Benefits and Pitfalls

## Begg's Funnel Plot – SE of the SMD – Effect of Monensin on Milk Fat Percentage





# Meta Analyses: Benefits and Pitfalls

## Monesin Milk Fat Bias

- In this case there are a large number of negative small studies, but very few small positive studies –
- There are two possibilities:
  - That the small positive studies do not exist
  - That they exist, but were not published
    - Either because they were small, different and rejected by a journal
    - OR that the scientists decided to keep them in ‘the top drawer’ and did not submit.



# Meta Analyses: Benefits and Pitfalls

## Heterogeneity – Variability

- Refers to the consistency of studies
- We consider this to be critical – the most important part of meta-analysis
- How is this measured –  $I^2$  (0 to 30 low; 30 -50 moderate, > 50 high) (based on  $Chi^2$  test)
- We know a lot about average responses! *Considerable progress will be made by understanding causes of variation*



# Meta Analyses: Benefits and Pitfalls

## Exploring Heterogeneity

- If clinical diversity (study/design or environment) causes statistical heterogeneity, meta-regression can be conducted
- Sub-group analysis can be used  
(Note: care if still heterogeneous)
- If the clinical diversity does not cause statistical heterogeneity then the point estimates are robust – i.e. really consistent results across a number of studies and environments

Study —


Standardised Mean diff.

(95% CI)

% Weight

- Schuler (1988)
- Sauer (1989)
- Sauer (1989)
- Erasmus (1993)
- Erasmus (1993)
- Vanderwerf (1998)
- Vanderwerf (1998)
- Vanderwerf (1998)
- Dhiman (1999)
- Dhiman (1999)
- Granzin (1999)
- Granzin (1999)
- Green (1999)
- Green (1999)
- Phipps (2000)
- Phipps (2000)
- Phipps (2000)
- Ruiz (2001)
- Broderick (2004)
- Broderick (2004)
- Green (2004)
- Green (2004)
- Green (2004)
- Green (2004)
- Green (2004)
- Green (2004)
- Green (2004)
- Green (2004)
- Green (2004)
- Green (2004)
- Green (2004)
- Green (2004)
- Green (2004)
- Erasmus (2005)
- Erasmus (2005)
- Granzin (2005)
- Granzin (2005)
- Gallardo (2005)
- Gallardo (2005)
- Gallardo (2005)
- Eifert (2005)
- Eifert (2005)
- Erasmus (2006)
- Erasmus (2006)
- Bell (2006)
- Bell (2006)
- Zahra (2006)
- Peterson-Wolfe (2007)
- Peterson-Wolfe (2007)
- Odongo (2007)
- Alzahal (2007)
- Alzahal (2007)
- Alzahal (2007)
- Grainger (2007)
- Overall (95% CI)

Effect Size  
 p-value: 0.001  
 Heterogeneity  
 chi-squared  
 p= 0.948  
 I<sub>2</sub> = 0



Study	Standardised Mean diff. (95% CI)	% Weight
Schuler (1988)	-0.28 (-1.53,0.97)	0.2
Sauer (1989)	-1.19 (-2.07,-0.32)	0.5
Sauer (1989)	-1.19 (-2.07,-0.32)	0.5
Erasmus (1993)	-0.03 (-0.65,0.59)	0.9
Erasmus (1993)	0.16 (-0.46,0.78)	0.9
Vanderwerf (1998)	0.00 (-0.69,0.70)	0.7
Vanderwerf (1998)	-0.06 (-0.76,0.63)	0.7
Vanderwerf (1998)	-0.14 (-0.83,0.55)	0.7
Dhiman (1999)	-0.29 (-1.09,0.52)	0.5
Dhiman (1999)	0.00 (-0.80,0.80)	0.5
Granzin (1999)	-0.62 (-2.28,1.03)	0.1
Granzin (1999)	2.96 (0.36,5.57)	0.1
Green (1999)	0.37 (-0.87,1.61)	0.2
Green (1999)	0.05 (-0.56,0.67)	0.9
Phipps (2000)	-0.06 (-0.78,0.65)	0.7
Phipps (2000)	-0.37 (-1.09,0.35)	0.7
Phipps (2000)	-0.31 (-1.03,0.41)	0.7
Ruiz (2001)	-0.19 (-0.91,0.53)	0.7
Broderick (2004)	-0.75 (-1.58,0.08)	0.5
Broderick (2004)	0.06 (-0.74,0.86)	0.5
Green (2004)	0.00 (-0.19,0.19)	9.2
Green (2004)	-0.03 (-0.23,0.16)	9.4
Green (2004)	-0.20 (-0.39,0.00)	9.1
Green (2004)	0.01 (-0.19,0.20)	9.2
Green (2004)	-0.08 (-0.28,0.11)	9.4
Green (2004)	-0.12 (-0.32,0.07)	9.1
Green (2004)	-0.09 (-0.46,0.28)	2.6
Green (2004)	-0.09 (-0.48,0.29)	2.4
Green (2004)	-0.26 (-0.63,0.12)	2.5
Green (2004)	0.04 (-0.32,0.41)	2.6
Green (2004)	0.00 (-0.38,0.38)	2.4
Green (2004)	-0.13 (-0.51,0.24)	2.5
Erasmus (2005)	-0.55 (-1.45,0.34)	0.4
Erasmus (2005)	0.00 (-0.88,0.88)	0.5
Granzin (2005)	-0.13 (-0.94,0.67)	0.5
Granzin (2005)	-0.47 (-1.28,0.34)	0.5
Gallardo (2005)	-0.02 (-0.54,0.49)	1.3
Gallardo (2005)	-0.01 (-0.53,0.50)	1.3
Gallardo (2005)	-0.12 (-0.64,0.40)	1.3
Eifert (2005)	0.31 (-1.09,1.71)	0.2
Eifert (2005)	0.00 (-1.39,1.39)	0.2
Erasmus (2006)	-0.12 (-0.99,0.76)	0.5
Erasmus (2006)	0.13 (-0.75,1.01)	0.5
Bell (2006)	-0.10 (-1.15,0.95)	0.3
Bell (2006)	0.58 (-0.50,1.65)	0.3
Zahra (2006)	-0.15 (-0.44,0.14)	4.1
Peterson-Wolfe (2007)	-0.15 (-0.57,0.26)	2.0
Peterson-Wolfe (2007)	-0.30 (-0.71,0.12)	2.0
Odongo (2007)	-0.48 (-1.29,0.33)	0.5
Alzahal (2007)	-0.40 (-1.21,0.40)	0.5
Alzahal (2007)	0.17 (-0.63,0.97)	0.5
Alzahal (2007)	0.35 (-0.46,1.15)	0.5
Grainger (2007)	-0.12 (-1.17,0.93)	0.3
Overall (95% CI)	-0.10 (-0.16,-0.04)	

-5.56895

0

5.56895

Standardised Mean diff.





# Meta Analyses: Benefits and Pitfalls

## Meta-Regression


- To investigate whether heterogeneity is related to specific characteristics of the studies (e.g. dose rate)
- To investigate whether particular covariates (potential ‘effect modifier’) explain any of the heterogeneity
- To identify evidence of different effects in subgroups



## Meta Analyses: Benefits and Pitfalls Protein and Fertility (Lean et al, 2012)

- This study highlighted two important matters
- Individual nutrition and fertility studies are almost inevitably confounded e.g. increase the protein meal do you change the NFC?
- There is benefit in exploring even consistent findings with meta-regression

Study	Diets	Preg	Duration	Parity	RR (95% CI)	Events, Treatment	Events, Control	Weight (M-H)
Jordan & Swa (1979)-1	Intermediate CP 16.3%	Estimated PR	94		0.80 (0.44, 1.45)	8/15	10/15	1.70
Jordan & Swa (1979)-2	High CP 19.3%	Estimated PR	94		0.60 (0.29, 1.23)	6/15	10/15	1.70
Edwards et al. (1980)-1	15% CP	Estimated PR	300	M	1.14 (0.53, 2.48)	8/18	7/18	1.19
Edwards et al. (1980)-2	17% CP	Estimated PR	300	M	1.14 (0.53, 2.48)	8/18	7/18	1.19
Folman et al. (1981)-1	16% CP	CR- (d 40-50)	122	M	1.21 (0.75, 1.95)	14/20	11/19	1.92
Folman et al. (1981)-2	20% CP	CR- (d 40-50)	122	M	0.78 (0.42, 1.44)	9/20	11/19	1.92
Bruckental. (1986)-1	Medium protein group (MP)	Estimated PR		B	0.75 (0.38, 1.50)	6/12	8/12	1.36
Bruckental. (1986)-2	High protein group (HP)	Estimated PR		B	0.88 (0.47, 1.63)	7/12	8/12	1.36
Howard (1987)	20%CP	% pregnant	139	M	1.00 (0.85, 1.18)	40/47	46/54	7.28
Caroll et al. (1988)	20% CP (Seperately fed)	1st service CR	95	B	0.87 (0.58, 1.32)	16/28	19/29	3.17
Bruckental et al. (1989)-1	HSBM 21% CP	PR (wk 16)	112	B	0.90 (0.72, 1.13)	47/72	47/65	8.40
Bruckental et al. (1989)-2	PRM 21% CP	PR (wk 16)	168	B	0.72 (0.55, 0.95)	35/67	47/65	8.11
Canfield et al. (1990)-1	High protein cows	1st service CR	93	B	0.67 (0.27, 1.66)	5/16	7/15	1.23
Canfield et al. (1990)-2	High protein heifers (1st lact)	1st service CR	93	B	0.63 (0.26, 1.50)	5/16	8/16	1.36
Elrod & Butler (1993)	High protein (Heifers)	1st service CR		P	0.74 (0.56, 0.99)	25/41	32/39	5.58
Sklan & Tinsky (1993)	Doublepro	1st service CR	120	M	1.19 (0.90, 1.59)	37/53	31/53	5.27
Carroll et al. (1994)	Soybean meal plus fishmeal	1st service CR	113	B	1.10 (0.80, 1.51)	23/31	21/31	3.57
Barton et al. (1996)	20% CP	1st service CR	110	M	1.08 (0.61, 1.91)	14/32	13/32	2.21
Son et al. (1996)	High & low Fat, Low Escape Protein	1st service CR	70	M	1.49 (0.79, 2.83)	14/30	10/32	1.65
Burke et al. (1997)-1	Dairy A Fishmeal	1st service CR	133	M	0.96 (0.74, 1.25)	65/160	67/159	11.43
Burke et al. (1997)-2	Dairy B Fishmeal	1st service CR	133	M	1.13 (0.71, 1.78)	33/150	26/133	4.69
Garcia-Bojalil et al. (1998)-1	15.7%DIP 0%Fat	Estimated PR	120	M	1.00 (0.40, 2.50)	5/11	5/11	0.85
Garcia-Bojalil et al. (1998)-2	15.7%DIP 2.2%Fat	Estimated PR	120	M	1.47 (0.43, 5.01)	4/10	3/11	0.49
McCormick et al. (1999)-1	Early lact HPMRUP	1st service PR	120	B	0.94 (0.61, 1.46)	24/62	25/61	4.28
McCormick et al. (1999)-2	Early lact MPMRUP	1st service PR	120	M	0.59 (0.34, 1.02)	14/58	25/61	4.14
Bruckental et al. (2000)-1	16.7% 32%RUP	1st service CR (d 45)	88	M	0.75 (0.20, 2.75)	3/14	4/14	0.68
Bruckental et al. (2000)-2	18.0% 35%RUP	1st service CR (d 45)	88	M	1.00 (0.31, 3.23)	4/14	4/14	0.68
Westwood et al. (2000)	HD Lac	1st service PR	171	M	0.75 (0.48, 1.19)	17/40	22/39	3.79
Chapa et al. (2001)-1	HCP 22.8% CP	1st service PR	195	M	0.43 (0.18, 1.04)	5/22	10/19	1.82
Chapa et al. (2001)-2	MCP 16.6% CP	1st service PR	204	M	0.42 (0.16, 1.11)	4/18	10/19	1.65
Law et al. (2009)-1	15% CP	1st service PR	150	B	1.14 (0.74, 1.77)	17/27	16/29	2.62
Law et al. (2009)-2	18% CP	1st service PR	150	B	0.94 (0.58, 1.52)	15/29	16/29	2.72
M-H Overall (I-squared = 0.0%, p = 0.536)					0.91 (0.84, 0.98)	537/1178	586/1158	100.00
D+L Overall					0.92 (0.86, 1.00)			



Reduces risk of pregnancy | Increases risk of pregnancy

with estimated predictive interval


.161 1 6.21



# Meta Analyses: Benefits and Pitfalls

## Protein and Reproduction


### NFC and Soluble Protein % CP






































# Meta Analyses: Benefits and Pitfalls

## Protein and Reproduction NFC and RDP



Jordan & Swa (1979)-1	0.02		0.80 [ 0.44 , 1.45 ]
Jordan & Swa (1979)-2	0.02		0.60 [ 0.29 , 1.23 ]
Edwards et al. (1980)-1	-0.14		1.14 [ 0.53 , 2.48 ]
Edwards et al. (1980)-2	-0.25		1.14 [ 0.53 , 2.48 ]
Folman et al. (1981)-1	-0.01		1.21 [ 0.75 , 1.95 ]
Folman et al. (1981)-2	0.01		0.78 [ 0.42 , 1.44 ]
Bruckental. (1986)-1	-0.22		0.75 [ 0.38 , 1.50 ]
Bruckental. (1986)-2	-0.43		0.88 [ 0.47 , 1.63 ]
Howard (1987)	0.12		1.00 [ 0.85 , 1.18 ]
Caroll et al. (1988)	-0.29		0.87 [ 0.58 , 1.32 ]
Bruckental et al. (1989)-1	-0.49		0.90 [ 0.72 , 1.13 ]
Bruckental et al. (1989)-2	-0.26		0.72 [ 0.55 , 0.95 ]
Canfield et al. (1990)-1	-0.32		0.67 [ 0.27 , 1.66 ]
Canfield et al. (1990)-2	-0.22		0.62 [ 0.26 , 1.50 ]
Elrod & Butler (1993)	-0.49		0.74 [ 0.56 , 0.99 ]
Sklan & Tinsky (1993)	-0.13		1.19 [ 0.90 , 1.59 ]
Carroll et al. (1994)	-0.03		1.10 [ 0.80 , 1.51 ]
Barton et al. (1996)	-0.22		1.08 [ 0.61 , 1.91 ]
Son et al. (1996)	-0.36		1.49 [ 0.79 , 2.83 ]
Burke et al. (1997)-1	-0.05		0.96 [ 0.74 , 1.25 ]
Burke et al. (1997)-2	-0.12		1.13 [ 0.71 , 1.78 ]
Garcia-Bojalil et al. (1998)-1	-0.77		1.00 [ 0.40 , 2.50 ]
Garcia-Bojalil et al. (1998)-2	-0.82		1.47 [ 0.43 , 5.01 ]
McCormick et al. (1999)-1	-0.5		0.94 [ 0.61 , 1.46 ]
McCormick et al. (1999)-2	-0.3		0.59 [ 0.34 , 1.02 ]
Bruckental et al. (2000)-1	-0.32		0.75 [ 0.20 , 2.75 ]
Bruckental et al. (2000)-2	0.2		1.00 [ 0.31 , 3.23 ]
Westwood et al. (2000)	-1.26		0.75 [ 0.48 , 1.19 ]
Chapa et al. (2001)-1	-0.28		0.43 [ 0.18 , 1.04 ]
Chapa et al. (2001)-2	-0.26		0.42 [ 0.16 , 1.11 ]
Law et al. (2009)-1	-0.23		1.14 [ 0.74 , 1.77 ]
Law et al. (2009)-2	-0.43		0.94 [ 0.58 , 1.52 ]



Relative Risk (log scale)



# Meta Analyses: Benefits and Pitfalls

## Summary

- The use of Meta-analyses is an excellent tool to identify the value of an intervention
  - With a proper analysis, one can:
    - Estimate the return on investment
    - Identify the conditions under which one will get the best responses
    - Ask the critical questions about the biology and what studies need to be done in the future
- As you look at meta-analyses for proposed interventions, follow the check lists to ensure that the intervention is valid and will be of value to the dairies you serve



# Meta Analyses: Benefits and Pitfalls

## Summary

- Boil it down and there is one simple message:
  - Proper pooling of all suitable studies is a lot more powerful than any one study and provides the best information on whether a product or a intervention works and under what circumstance





# Meta Analyses: Benefits and Pitfalls

## Questions & Answers

The Fatty Acid Forum sponsored by **VIRTUS**  
NUTRITION™